Patents by Inventor Susanne Bang
Susanne Bang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9187549Abstract: The present invention relates to Vitamin K-dependent protein compositions having a very low, or negligible, content of protein contaminants. The present invention also relates to method applicable in the preparation of such Vitamin K-dependent protein compositions. Such methods may either be used alone or in sequential combination with the purpose of reducing the relative content of protein contaminants. The present invention is particularly relevant in the preparation of compositions of coagulation factors selected from Factor X polypeptides (FX/FXa), Factor IX polypeptides (FIX/FIXa), Factor VII polypeptides (FVII/FVIIa), and the anticoagulant Protein C, in particular Factor VII polypeptides.Type: GrantFiled: December 23, 2005Date of Patent: November 17, 2015Assignee: Novo Nordisk Healthcare A/GInventors: Janus Krarup, Thomas Budde Hansen, Anne Charlotte Arentsen, Daniel E. Rasmussen, Are Bogsnes, Arne Staby, Haleh Ahmadian, Susanne Bang
-
Patent number: 8426566Abstract: The invention is related to a method for purification of recombinant proteins using highly basic proteins from thermophilic bacteria as purification tags for use in a cation-exchange chromatography purification step. The basic proteins may be ribosomal proteins. The recombinant proteins are expressed in eukaryotic or prokaryotic host cells. The purification tag will typically have a pl above about 9 and comprise from about 15 to about 250 amino acid residues.Type: GrantFiled: December 1, 2011Date of Patent: April 23, 2013Assignee: Novo Nordisk HealthCare AGInventors: Allan Christian Shaw, Susanne Bang, Jing Su
-
Patent number: 8399620Abstract: A method for purifying a recombinant protein using a multimodal or mixed mode resin containing ligands which comprise a hydrophobic part and a negatively charged part is described. The invention is advantageous in that it is a single step chromatographic process which does not require adjustment of pH or conductivity during loading step and results in high yield and potency. The process is used for the purification of recombinant compositions of coagulation factor, particularly recombinant Factor VIII.Type: GrantFiled: July 11, 2008Date of Patent: March 19, 2013Assignee: Novo Nordisk A/SInventors: Susanne Bang, Lars Thim, Johan Karlsson
-
Patent number: 8383776Abstract: The invention relates to a method for purifying a factor XIII polypeptide from a biological material, the method comprising subjecting the material to sequential chromatography on an anion-exchange matrix and a hydrophobic interaction matrix.Type: GrantFiled: July 19, 2010Date of Patent: February 26, 2013Assignee: Novo Nordisk Health Care AGInventor: Susanne Bang
-
Publication number: 20120083027Abstract: The invention is related to a method for purification of recombinant proteins using highly basic proteins from thermophilic bacteria as purification tags for use in a cation-exchange chromatography purification step. The basic proteins may be ribosomal proteins. The recombinant proteins are expressed in eukaryotic or prokaryotic host cells. The purification tag will typically have a pl above about 9 and comprise from about 15 to about 250 amino acid residues.Type: ApplicationFiled: December 1, 2011Publication date: April 5, 2012Applicant: Novo Nordisk A/SInventors: Allan Christian Shaw, Susanne Bang, Jing Su
-
Patent number: 8137929Abstract: The invention is related to a method for purification of recombinant proteins using highly basic proteins from thermophilic bacteria as purification tags for use in a cation-exchange chromatography purification step. The basic proteins may be ribosomal proteins. The recombinant proteins are expressed in eukaryotic or prokaryotic host cells. The purification tag will typically have a pl above about 9 and comprise from about 15 to about 250 amino acid residues.Type: GrantFiled: April 10, 2006Date of Patent: March 20, 2012Assignee: Novo Nordisk Health Care AGInventors: Allan Christian Shaw, Susanne Bang, Jing Su
-
Publication number: 20100297098Abstract: The invention relates to a method for purifying a factor XIII polypeptide from a biological material, the method comprising subjecting the material to sequential chromatography on an anion-exchange matrix and a hydrophobic interaction matrix.Type: ApplicationFiled: July 19, 2010Publication date: November 25, 2010Applicant: Novo Nordisk HealthCare A/GInventor: Susanne Bang
-
Publication number: 20100204452Abstract: A method for purifying a recombinant protein using a multimodal or mixed mode resin containing ligands which comprise a hydrophobic part and a negatively charged part is described. The invention is advantageous in that it is a single step chromatographic process which does not require adjustment of pH or conductivity during loading step and results in high yield and potency. The process is used for the purification of recombinant compositions of coagulation factor, particularly recombinant Factor VIII.Type: ApplicationFiled: July 11, 2008Publication date: August 12, 2010Applicant: Novo Nordisk Health Care AGInventors: Susanne Bang, Lars Thim, Johan Karlsson
-
Publication number: 20090306352Abstract: The invention is related to a method for purification of recombinant proteins using highly basic proteins from thermophilic bacteria as purification tags for use in a cation-exchange chromatography purification step. The basic proteins may be ribosomal proteins. The recombinant proteins are expressed in eukaryotic or prokaryotic host cells. The purification tag will typically have a pl above about 9 and comprise from about 15 to about 250 amino acid residues.Type: ApplicationFiled: April 10, 2006Publication date: December 10, 2009Applicant: Novo Nordisk A/SInventors: Allan Christian Shaw, Susanne Bang, Jing Su
-
Publication number: 20080207880Abstract: The present invention relates to Vitamin K-dependent protein compositions having a very low, or negligible, content of protein contaminants. The present invention also relates to method applicable in the preparation of such Vitamin K-dependent protein compositions. Such methods may either be used alone or in sequential combination with the purpose of reducing the relative content of protein contaminants. The present invention is particularly relevant in the preparation of compositions of coagulation factors selected from Factor X polypeptides (FX/FXa), Factor IX polypeptides (FIX/FIXa), Factor VII polypeptides (FVII/FVIIa), and the anticoagulant Protein C, in particular Factor VII polypeptides.Type: ApplicationFiled: December 23, 2005Publication date: August 28, 2008Applicant: Novo Nordisk HealthCare A/GInventors: Janus Krarup, Thomas Budde Hansen, Anne Charlotte Arentsen, Daniel E. Rasmussen, Are Bognes, Arne Staby, Haleh Ahmadian, Susanne Bang
-
Patent number: 7411039Abstract: The present invention relates to novel human glucagon-like peptide-2 (GLP-2) peptides and human glucagon-like peptide-2 derivatives which have a protracted profile of action as well as polynucleotide constructs encoding such peptides, vectors and host cells comprising and expressing the polynucleotide, pharmaceutical compositions, uses and methods of treatment.Type: GrantFiled: October 14, 2003Date of Patent: August 12, 2008Assignee: Novo Nordisk A/SInventors: Lars Thim, Susanne Bang, Niels Christian Kaarsholm, Anette Sams Nielsen, Nils Langeland Johansen, Kjeld Madsen, Magali Zundel, Peter Thygesen, Birgitte Michelsen
-
Publication number: 20080176789Abstract: The invention relates to a method for purifying a factor XIII polypeptide from a biological material, the method comprising subjecting the material to sequential chromatography on an anion-exchange matrix and a hydrophobic interaction matrix.Type: ApplicationFiled: August 26, 2005Publication date: July 24, 2008Applicant: Novc Nordisk HealthCare A/GInventor: Susanne Bang
-
Publication number: 20070213265Abstract: The invention described herein provides novel human Kunitz-type protease inhibitors; nucleic acids encoding such inhibitors; vectors and host cells comprising such nucleic acids; compositions comprising such inhibitors, cells, and/or nucleic acids; methods of producing such inhibitors, nucleic acids, vectors, compositions, and cells; and methods of inducing, promoting, and/or enhancing a physiological response in a subject by administering to the subject an amount of such an inhibitor, nucleic acid, vector, host cell, and/or composition sufficient to induce such a physiological response.Type: ApplicationFiled: April 12, 2006Publication date: September 13, 2007Applicant: Novo Nordisk A/SInventors: Marianne Jorgensen, Susanne Bang, Ole Olsen, Lars Petersen
-
Publication number: 20040152633Abstract: The invention described herein provides novel human Kunitz-type protease inhibitors; nucleic acids encoding such inhibitors; vectors and host cells comprising such nucleic acids; compositions comprising such inhibitors, cells, and/or nucleic acids; methods of producing such inhibitors, nucleic acids, vectors, compositions, and cells; and methods of inducing, promoting, and/or enhancing a physiological response in a subject by administering to the subject an amount of such an inhibitor, nucleic acid, vector, host cell, and/or composition sufficient to induce such a physiological response.Type: ApplicationFiled: November 25, 2003Publication date: August 5, 2004Inventors: Marianne Ulrich Jorgensen, Susanne Bang, Ole Hvilsted Olsen, Lars Christian Petersen
-
Publication number: 20040122210Abstract: The present invention relates to novel human glucagon-like peptide-2 (GLP-2) peptides and human glucagon-like peptide-2 derivatives which have a protracted profile of action as well as polynucleotide constructs encoding such peptides, vectors and host cells comprising and expressing the polynucleotide, pharmaceutical compositions, uses and methods of treatment.Type: ApplicationFiled: October 14, 2003Publication date: June 24, 2004Inventors: Lars Thim, Susanne Bang, Morten Schlein, Niels Christian Kaarsholm, Dorthe Kot Engelund, Anette Sams Nielsen, Nils Langeland Johansen, Kjeld Madsen, Magali Zundel, Peter Thygesen